WO2013109229A1 - Tablet formulations comprising cefixime as active agent - Google Patents

Tablet formulations comprising cefixime as active agent Download PDF

Info

Publication number
WO2013109229A1
WO2013109229A1 PCT/TR2013/000042 TR2013000042W WO2013109229A1 WO 2013109229 A1 WO2013109229 A1 WO 2013109229A1 TR 2013000042 W TR2013000042 W TR 2013000042W WO 2013109229 A1 WO2013109229 A1 WO 2013109229A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
cefixime
pharmaceutical
formulation
formulation according
Prior art date
Application number
PCT/TR2013/000042
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109229A1 publication Critical patent/WO2013109229A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to pharmaceutical tablet formulations comprising cefixime to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
  • Cefixime was first disclosed in the patent application numbered EP0030630 (Bl). In said document, cefixime was indicated to be effective in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
  • Cefixime is available in the form of 200 and 400 mg oral tablets or oral suspension on the market.
  • a physical parameter essential in tablet formulations is its hardness.
  • the hardness value of a tablet shows its resistance to storage, transport, coating, erosion and breakage before usage. As this value decreases, tablet becomes more sensitive to the loss of active agent and thus the amount of dose taken decreases. Tablets having low hardness value are more exposed to erosion during coating process and this case results in dosage forms having uneven surfaces and variable amounts of active agent in the final product while producing coated tablet forms.
  • tablet hardness is closely related to two other physical properties of the tablet: dispersibility and solubility. Tablets with high hardness do not disperse easily or dissolve adequately; decreasing the bioavailability of said dosage forms and therefore the time for desired biological response to occur will extend. The same case is also true for all types of tablets such as effervescent, film-coated, soluble, extended-release, modified-release, delayed- release tablets etc.
  • Types of active agents and excipients used, particle sizes thereof, flowability of the powder or granules to be granulated influence attaining appropriate tablet hardness.
  • the desired hardness value of tablets are aimed to be low enough to disintegrate fast in the stomach but high enough to preserve tablet uniformity during packaging, carrying and storing phases from the time of production until used by patient.
  • a characteristic feature of the tablet formulations of the present invention is that the tablet hardness value is between 3 kP and 50 kP and the amount of diluent in the formulation is in the range of 20-80%, preferably 30-70%, more preferably 40- 60% by weight.
  • Another characteristic feature of the present invention is that the tablet hardness value is between 4 kP and 40 kP and the amount of diluent in the formulation is in the range of 30- 70% by weight.
  • a further characteristic feature of the present invention is that the tablet hardness value is between 5 kP and 30 kP and the amount of diluent in the formulation is in the range of 40- 60% by weight.
  • tablette used throughout the text refers to tablet forms such as tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet.
  • the tablet form to be used is film-coated tablet.
  • the pharmaceutical formulation of the present invention is preferably in the form of film- coated tablet.
  • the pharmaceutical tablet formulation of the present invention can be treated with film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
  • film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
  • saccharose can be used alone or together with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
  • agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
  • Water-soluble film coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; polysaccharides such as pullulan or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone
  • polysaccharides such as pullulan or combinations thereof.
  • Enteric coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate
  • acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof.
  • a film coating agent branded as Opadry® can be used in the present invention.
  • Cefixime comprised in the pharmaceutical formulations of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in crystalline, amorphous forms or combinations thereof in terms of polymorphic structure.
  • Cefixime is preferably in the form of hydrate, more preferably in the form of cefixime trihydrate.
  • the pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient selected from a group comprising diluent, lubricant.
  • the diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
  • the lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polythylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
  • the pharmaceutical formulations of the invention comprising cefixime as active agent comprise cefixime in the range of 20-70%, preferably in the range of 30-60%, more preferably in the range of 25-55% by weight.
  • the preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation into tablet form under an appropriate compression force.
  • the amount of the appropriate excipients composing the pharmaceutical tablet formulations of the present invention are adjusted with regard to the amount cefixime in order to provide the desired dispersibility and solubility of the dosage form.
  • the ratio of cefixime to diluent should be in the range of 1 : 10 to 10:1 by weight in order to attain the required dispersibility.
  • another feature of the tablet formulations of the present invention is that the ratio of cefixime to diluent should be in the range of 1 : 10 to 10:1, preferably 1 :5 to 5: 1, more preferably 1 :3 to 3:1 by weight.
  • the pharmaceutical tablet formulations of the present invention comprise cefixime in the range of 20-70% and lubricant 0.5-3.5% by weight.
  • the preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation into tablet form under an appropriate compression force.
  • the tablet formulations of the invention can be produced in accordance with the production method given below comprising following steps; 1. Mixing cefixime and diluent(s),
  • the inventors of the present invention have remarked during the development studies of cefixime tablet formulations that the use of 50% of the lubricant in the second step and the rest of the lubricant during lubrication in the fourth step improved the homogeneity of the formulation during production and prevented the loss of active agent. Accordingly, the production method used for the tablet formulations of the present invention is characterized in that 50%of the lubricant is used in the second step of the process to form a blend and the rest of the lubricant is used in the fourth step to lubricate the blend.
  • the pharmaceutical composition of the invention can be used in the prevention and treatment of the infectious diseases caused by gram positive and gram negative bacteria.
  • the production method to be applied for the tablet formulations to be prepared according to the formulation given above comprises the following steps;

Abstract

The present invention relates to pharmaceutical tablet formulations comprising cefixime to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.

Description

TABLET FORMULATIONS COMPRISING CEFIXIME AS ACTIVE AGENT
The present invention relates to pharmaceutical tablet formulations comprising cefixime to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria. Cefixime was first disclosed in the patent application numbered EP0030630 (Bl). In said document, cefixime was indicated to be effective in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
Cefixime is available in the form of 200 and 400 mg oral tablets or oral suspension on the market. A physical parameter essential in tablet formulations is its hardness. The hardness value of a tablet shows its resistance to storage, transport, coating, erosion and breakage before usage. As this value decreases, tablet becomes more sensitive to the loss of active agent and thus the amount of dose taken decreases. Tablets having low hardness value are more exposed to erosion during coating process and this case results in dosage forms having uneven surfaces and variable amounts of active agent in the final product while producing coated tablet forms.
On the other hand, tablet hardness is closely related to two other physical properties of the tablet: dispersibility and solubility. Tablets with high hardness do not disperse easily or dissolve adequately; decreasing the bioavailability of said dosage forms and therefore the time for desired biological response to occur will extend. The same case is also true for all types of tablets such as effervescent, film-coated, soluble, extended-release, modified-release, delayed- release tablets etc.
Types of active agents and excipients used, particle sizes thereof, flowability of the powder or granules to be granulated influence attaining appropriate tablet hardness. The desired hardness value of tablets are aimed to be low enough to disintegrate fast in the stomach but high enough to preserve tablet uniformity during packaging, carrying and storing phases from the time of production until used by patient.
Development studies conducted by the inventors of the present invention have shown that the required hardness and dissolution rate of tablets containing cefixime are obtained when the tablet hardness value is between 3 kP and 50 kP and the amount of diluent in the formulation is in the range of 20-80% by weight. Based on these studies, a characteristic feature of the tablet formulations of the present invention is that the tablet hardness value is between 3 kP and 50 kP and the amount of diluent in the formulation is in the range of 20-80%, preferably 30-70%, more preferably 40- 60% by weight. Another characteristic feature of the present invention is that the tablet hardness value is between 4 kP and 40 kP and the amount of diluent in the formulation is in the range of 30- 70% by weight.
A further characteristic feature of the present invention is that the tablet hardness value is between 5 kP and 30 kP and the amount of diluent in the formulation is in the range of 40- 60% by weight.
The term "tablet" used throughout the text refers to tablet forms such as tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet. In a preferred embodiment of the invention, the tablet form to be used is film-coated tablet. The pharmaceutical formulation of the present invention is preferably in the form of film- coated tablet.
The pharmaceutical tablet formulation of the present invention can be treated with film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
As sugar-based coating agent, saccharose can be used alone or together with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
Water-soluble film coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; polysaccharides such as pullulan or combinations thereof.
Enteric coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
Other film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof. For example, a film coating agent branded as Opadry® can be used in the present invention.
Cefixime comprised in the pharmaceutical formulations of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in crystalline, amorphous forms or combinations thereof in terms of polymorphic structure. Cefixime is preferably in the form of hydrate, more preferably in the form of cefixime trihydrate.
The pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient selected from a group comprising diluent, lubricant.
The diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
The lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polythylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
The pharmaceutical formulations of the invention comprising cefixime as active agent comprise cefixime in the range of 20-70%, preferably in the range of 30-60%, more preferably in the range of 25-55% by weight.
The preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation into tablet form under an appropriate compression force.
The amount of the appropriate excipients composing the pharmaceutical tablet formulations of the present invention are adjusted with regard to the amount cefixime in order to provide the desired dispersibility and solubility of the dosage form. In accordance with the studies examining this aspect of the cefixime formulation, the inventors have surprisingly observed that the ratio of cefixime to diluent should be in the range of 1 : 10 to 10:1 by weight in order to attain the required dispersibility. In the light of these studies, another feature of the tablet formulations of the present invention is that the ratio of cefixime to diluent should be in the range of 1 : 10 to 10:1, preferably 1 :5 to 5: 1, more preferably 1 :3 to 3:1 by weight.
The pharmaceutical tablet formulations of the present invention comprise cefixime in the range of 20-70% and lubricant 0.5-3.5% by weight. The preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation into tablet form under an appropriate compression force.
The tablet formulations of the invention can be produced in accordance with the production method given below comprising following steps; 1. Mixing cefixime and diluent(s),
2. Adding 50% of the lubricant to form a blend,
3. Compacting said blend and sieving it,
4. Lubricating formed blend with the rest of the lubricant,
5. Compressing formed blend into tablet dosage form and 6. Coating obtained tablets with a coating solution containing a film-coating agent.
The inventors of the present invention have remarked during the development studies of cefixime tablet formulations that the use of 50% of the lubricant in the second step and the rest of the lubricant during lubrication in the fourth step improved the homogeneity of the formulation during production and prevented the loss of active agent. Accordingly, the production method used for the tablet formulations of the present invention is characterized in that 50%of the lubricant is used in the second step of the process to form a blend and the rest of the lubricant is used in the fourth step to lubricate the blend. The pharmaceutical composition of the invention can be used in the prevention and treatment of the infectious diseases caused by gram positive and gram negative bacteria.
The examples below are given to explain the pharmaceutical compositions of the invention and the preparation methods thereof; the scope of the invention cannot be limited to these examples.
EXAMPLE
1. Film-Coated Tablet Formulation
Figure imgf000006_0001
The production method to be applied for the tablet formulations to be prepared according to the formulation given above comprises the following steps;
1. Mixing cefixime and diluent(s),
2. Adding 50% of the lubricant to form a blend,
3. Compacting said blend and sieving it,
4. the rest of the lubricant is added to the formed blend,
5. Compressing formed blend into tablet dosage form and
6. Coating obtained tablets with a solution containing a film-coating agent.

Claims

1. A pharmaceutical tablet formulation comprising cefixime as active agent with at least one pharmaceutically acceptable excipient, characterized in that tablet hardness value of said tablet formulation is between 3 and 50 kP and the amount of diluent in the formulation is in the range of 20-80% by weight.
2. The pharmaceutical tablet formulation according to claim 1, characterized in that tablet hardness value of said tablet formulation is between 4 and 40 kP and the amount of diluent in the formulation is in the range of 30-70% by weight.
3. The pharmaceutical tablet formulation according to claims 1-2, characterized in that tablet hardness value of said tablet formulation is between 5 and 30 kP and the amount of diluent in the formulation is in the range of 40-60%) by weight.
4. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that said tablet formulation is in the form of any of tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet dosage forms.
5. The pharmaceutical tablet formulation according to claim 4, characterized in that said formulation is in the form of film-coated tablet.
6. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that cefixime is in the form of cefixime trihydrate.
7. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that at least one pharmaceutically acceptable excipient to be used with cefixime is selected from the group comprising diluent, lubricant.
8. The pharmaceutical tablet formulation according to claim 7, wherein diluent is selected from the group comprising of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
9. The pharmaceutical tablet formulation according to claim 7, wherein lubricant is selected from the group comprising of calcium stearate, magnesium stearate, polythylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
10. The pharmaceutical formulation according to any of the preceding claims, characterized in that the ratio of cefixime to diluent is the range of 1 :10 to 10:1 by weight.
11. The pharmaceutical formulation according to claim 10, characterized in that the ratio of cefixime to diluent is the range of 1 :5 to 5 : 1 by weight.
12. The pharmaceutical formulation according to claim 11, characterized in that the ratio of cefixime to diluent is the range of 1 :3 to 3:1 by weight.
13. The pharmaceutical formulation according to any of the preceding claims, wherein said formulation comprises cefixime in the range of 20-70% by weight.
14. The pharmaceutical formulation according to claim 13, wherein said formulation comprises cefixime in the range of 30-60% by weight.
15. The pharmaceutical formulation according claim 14, wherein said formulation comprises cefixime in the range of 25-55%) by weight.
16. The pharmaceutical formulation according to any of the preceding claims, wherein said formulation comprises cefixime in the range of 20-70%) and lubricant 0.5-3.5%) by weight.
17. The process for the preparation of a pharmaceutical composition according to any of the preceding claims, wherein said process comprises the following steps
1. Mixing cefixime and diluent(s), 2. Adding 50%» of the lubricant to form a blend,
3. Compacting said blend and sieving it,
4. the rest of the lubricant is added to the formed blend,
5. Compressing formed blend into tablet dosage form and
6. Coating obtained tablets with a solution containing a film-coating agent.
PCT/TR2013/000042 2012-01-18 2013-01-18 Tablet formulations comprising cefixime as active agent WO2013109229A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00594 2012-01-18
TR201200594 2012-01-18

Publications (1)

Publication Number Publication Date
WO2013109229A1 true WO2013109229A1 (en) 2013-07-25

Family

ID=48237236

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000041 WO2013109228A1 (en) 2012-01-18 2013-01-18 Formulations comprising cefixime as active agent
PCT/TR2013/000042 WO2013109229A1 (en) 2012-01-18 2013-01-18 Tablet formulations comprising cefixime as active agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000041 WO2013109228A1 (en) 2012-01-18 2013-01-18 Formulations comprising cefixime as active agent

Country Status (1)

Country Link
WO (2) WO2013109228A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030630B1 (en) 1979-11-19 1987-04-01 Fujisawa Pharmaceutical Co., Ltd. 7-acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation
CN1803138A (en) * 2006-01-09 2006-07-19 深圳市制药厂 Cefixime oral disintegration tablet and its preparation method
CN101606913A (en) * 2009-07-16 2009-12-23 广州白云山制药股份有限公司广州白云山制药总厂 Cefixime dispersible tablet and preparation method thereof
WO2011093822A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Effervescent formulations comprising cefixime and clavulanic acid as active agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
US7632520B2 (en) * 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
CN100417383C (en) * 2006-03-07 2008-09-10 中国药科大学 Effervescent tablet containing cefixime and its preparing method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030630B1 (en) 1979-11-19 1987-04-01 Fujisawa Pharmaceutical Co., Ltd. 7-acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation
CN1803138A (en) * 2006-01-09 2006-07-19 深圳市制药厂 Cefixime oral disintegration tablet and its preparation method
CN101606913A (en) * 2009-07-16 2009-12-23 广州白云山制药股份有限公司广州白云山制药总厂 Cefixime dispersible tablet and preparation method thereof
WO2011093822A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Effervescent formulations comprising cefixime and clavulanic acid as active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANDIP KUMER MANGAL BHAI PATEL ET AL.: "Formulation, development and evaluation of film coated tablet containing Cefixime and Potassium clavulanate", JOURNAL OF PHARMACY RESEARCH, vol. 4, no. 6, 11 June 2011 (2011-06-11), pages 1861 - 1863, XP002698642, ISSN: 0974-6943 *

Also Published As

Publication number Publication date
WO2013109228A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
CN106943355B (en) Pharmaceutical composition
US20150272891A1 (en) Dosage forms comprising apixaban and matrix former
WO2019086725A2 (en) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
JP2008521932A5 (en)
WO2014086857A1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
US20170231969A1 (en) Pharmaceutical Compositions of Edoxaban
WO2009027786A2 (en) Matrix dosage forms of varenicline
WO2013109227A1 (en) Pharmaceutical compositions comprising ceftibuten
WO2007069274A2 (en) Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
JP2013043834A (en) Elution improving solid preparation
JP2023036924A (en) Pharmaceutical composition containing lenalidomide
WO2010120963A1 (en) Tablet formulation for p38 inhibitor and method
JP7117975B2 (en) Pharmaceutical composition containing teneligliptin, method for producing pharmaceutical composition containing teneligliptin, tablet containing teneligliptin, and method for producing tablet containing teneligliptin
WO2014057059A1 (en) Effervescent cefdinir formulation
WO2013109229A1 (en) Tablet formulations comprising cefixime as active agent
WO2013109205A1 (en) Pharmaceutical tablet formulations comprising cefetamet
US20080260785A1 (en) Paroxetine compositions
WO2013109226A1 (en) Pharmaceutical tablet formulations comprising cefuroxime
Kumar et al. Formulation and evaluation of matrix tablets of acarbose
EP2875807B1 (en) Tablet formulation of colesevelam
WO2013109203A1 (en) Tablet formulations comprising cefditoren pivoxil
AU2010250750A1 (en) Pharmaceutical composition of olanzapine and process for their preparation
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
JP2008133231A (en) Pharmaceutical composition having improved photostability
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13720147

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13720147

Country of ref document: EP

Kind code of ref document: A1